Literature DB >> 26516195

Immunotherapy for non-small cell lung cancer: current concepts and clinical trials.

Marissa Mayor1, Neng Yang1, Daniel Sterman2, David R Jones1, Prasad S Adusumilli3.   

Abstract

Recent successes in immunotherapeutic strategies are being investigated to combat cancers that have less than ideal responses to standard of care treatment, such as non-small-cell lung cancer. In this paper, we summarize concepts and the current status of immunotherapy for non-small cell lung cancer, including salient features of the major categories of immunotherapy-monoclonal antibody therapy, immune checkpoint blockade, immunotoxins, anticancer vaccines, and adoptive cell therapy.
© The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Adoptive cell therapy; Antibody therapy; Chimeric antigen receptor; Lung cancer; PD-1/PD-L1 blockade

Mesh：

Substances：

Year:  2015        PMID： 26516195      PMCID： PMC4851162          DOI： 10.1093/ejcts/ezv371

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN： 1010-7940            Impact factor:   4.191


  67 in total

Review 1.  Vaccination therapy for non-small-cell lung cancer.

Authors:  Kristof Cuppens; Johan Vansteenkiste
Journal:  Curr Opin Oncol       Date:  2014-03       Impact factor: 3.645

2.  Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

Authors:  Scott N Gettinger; Leora Horn; Leena Gandhi; David R Spigel; Scott J Antonia; Naiyer A Rizvi; John D Powderly; Rebecca S Heist; Richard D Carvajal; David M Jackman; Lecia V Sequist; David C Smith; Philip Leming; David P Carbone; Mary C Pinder-Schenck; Suzanne L Topalian; F Stephen Hodi; Jeffrey A Sosman; Mario Sznol; David F McDermott; Drew M Pardoll; Vindira Sankar; Christoph M Ahlers; Mark Salvati; Jon M Wigginton; Matthew D Hellmann; Georgia D Kollia; Ashok K Gupta; Julie R Brahmer
Journal:  J Clin Oncol       Date:  2015-04-20       Impact factor: 44.544

3.  Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

Authors:  Thomas J Lynch; Igor Bondarenko; Alexander Luft; Piotr Serwatowski; Fabrice Barlesi; Raju Chacko; Martin Sebastian; Joel Neal; Haolan Lu; Jean-Marie Cuillerot; Martin Reck
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

Review 4.  γδ T cell therapy for the treatment of non-small cell lung cancer.

Authors:  Kazuhiro Kakimi; Hirokazu Matsushita; Tomohiro Murakawa; Jun Nakajima
Journal:  Transl Lung Cancer Res       Date:  2014-02

Review 5.  Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience.

Authors:  Håkan Mellstedt; Johan Vansteenkiste; Nick Thatcher
Journal:  Lung Cancer       Date:  2011-04-06       Impact factor: 5.705

6.  Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.

Authors:  Edward Y Woo; Heidi Yeh; Christina S Chu; Katia Schlienger; Richard G Carroll; James L Riley; Larry R Kaiser; Carl H June
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

Review 7.  Current clinical trials testing combinations of immunotherapy and radiation.

Authors:  Marka Crittenden; Holbrook Kohrt; Ronald Levy; Jennifer Jones; Kevin Camphausen; Adam Dicker; Sandra Demaria; Silvia Formenti
Journal:  Semin Radiat Oncol       Date:  2015-01       Impact factor: 5.934

8.  Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells.

Authors:  Jérémy Goc; Claire Germain; Thi Kim Duy Vo-Bourgais; Audrey Lupo; Christophe Klein; Samantha Knockaert; Luc de Chaisemartin; Hanane Ouakrim; Etienne Becht; Marco Alifano; Pierre Validire; Romain Remark; Scott A Hammond; Isabelle Cremer; Diane Damotte; Wolf-Herman Fridman; Catherine Sautès-Fridman; Marie-Caroline Dieu-Nosjean
Journal:  Cancer Res       Date:  2013-12-23       Impact factor: 12.701

9.  MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy.

Authors:  Preeta Tyagi; Beloo Mirakhur
Journal:  Clin Lung Cancer       Date:  2009-09       Impact factor: 4.785

10.  Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin.

Authors:  Dominic Fan; Seiji Yano; Hisashi Shinohara; Carmen Solorzano; Melissa Van Arsdall; Corazon D Bucana; Sen Pathak; Ewa Kruzel; Roy S Herbst; Amir Onn; Jennifer S Roach; Masanori Onda; Qing-cheng Wang; Ira Pastan; Isaiah J Fidler
Journal:  Mol Cancer Ther       Date:  2002-06       Impact factor: 6.009
View more
  13 in total

Review 1.  Monoclonal antibodies in cancer immunotherapy.

Authors:  Ilgin Kimiz-Gebologlu; Sultan Gulce-Iz; Cigir Biray-Avci
Journal:  Mol Biol Rep       Date:  2018-10-11       Impact factor: 2.316

2.  Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program.

Authors:  Reyes Bernabé-Caro; Pilar Garrido; Rosario García-Campelo; Ramón Palmero; Ángel Artal; Cristina Bayona; Delvys Rodríguez-Abreu; Marta López-Brea; Alfredo Paredes; David Vicente; José Miguel Sánchez Torres; Margarita Majem; Pilar Diz; Rocío Gordo; Margarita Coca; Javier de Castro
Journal:  Oncotarget       Date:  2022-06-15

3.  Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.

Authors:  Leonid Cherkassky; Aurore Morello; Jonathan Villena-Vargas; Yang Feng; Dimiter S Dimitrov; David R Jones; Michel Sadelain; Prasad S Adusumilli
Journal:  J Clin Invest       Date:  2016-07-25       Impact factor: 14.808

4.  Immunotherapy in anaplastic thyroid cancer.

Authors:  Maoguang Ma; Bo Lin; Mingdian Wang; Xiaoli Liang; Lei Su; Okenwa Okose; Weiming Lv; Jie Li
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

5.  The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials.

Authors:  Yangyang Xu; Bing Wan; Xi Chen; Ping Zhan; Yuan Zhao; Tianli Zhang; Hongbing Liu; Muhammad Zubair Afzal; Said Dermime; Steven N Hochwald; Paul Hofman; Hossein Borghaei; Dang Lin; Tangfeng Lv; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2019-08

Review 6.  Potential role of immunotherapy in advanced non-small-cell lung cancer.

Authors:  Ramon Andrade de Mello; Ana Flávia Veloso; Paulo Esrom Catarina; Sara Nadine; Georgios Antoniou
Journal:  Onco Targets Ther       Date:  2016-12-16       Impact factor: 4.147

7.  Myeloid-derived suppressor cells infiltration in non-small-cell lung cancer tumor and MAGE-A4 and NY-ESO-1 expression.

Authors:  Zhenbo Hou; Xiao Liang; Xinmei Wang; Ziqiang Zhou; Guilan Shi
Journal:  Oncol Lett       Date:  2020-03-31       Impact factor: 2.967

8.  MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.

Authors:  A Bouillez; H Rajabi; C Jin; M Samur; A Tagde; M Alam; M Hiraki; T Maeda; X Hu; D Adeegbe; S Kharbanda; K-K Wong; D Kufe
Journal:  Oncogene       Date:  2017-03-13       Impact factor: 9.867

9.  Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Binghao Zhao; Wenxiong Zhang; Dongliang Yu; Jianjun Xu; Yiping Wei
Journal:  Oncotarget       Date:  2017-07-19

10.  Inhaled Immunotherapy Administration for Lung Cancer; Efficient? Certainly Possible.

Authors:  Konstantinos Sapalidis; Paul Zarogoulidis; Haidong Huang; Chong Bai; Yuting Wen; Li Wang; Konstantina Boniou; Ilias Karapantzos; Chrysanthi Karapantzou; Michael Karanikas; Vasilis Thomaidis; Christoforos Kosmidis; Chrysanthi Sardeli; Naim Benhassen; Yan-Gao Man; Maria C Florou; Stylianos Mantalovas; Stella Laskou; Dimitris Giannakidis; Charilaos Koulouris; Aikaterini Amaniti; Isaak Kesisoglou; Wolfgang Hohenforst-Schmidt
Journal:  J Cancer       Date:  2018-03-02       Impact factor: 4.207
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.